Vaccine companies Valneva SE (Nasdaq:VALN) (Euronext Paris:VLA) and LimmaTech Biologics AG announced on Thursday a strategic partnership and licensing agreement for the development, manufacturing and commercialisation of Shigella4V (S4V), a tetravalent bioconjugate vaccine candidate against shigellosis.
Under the agreement Valneva has acquired an exclusive global licence for S4V.
The deal includes an upfront payment of EUR10m to LimmaTech as well as potential regulatory, development and sales-based milestone payments and low double-digit royalties on sales.
Shigellosis, a diarrhoeal disease caused by Shigella bacteria, affects millions worldwide, particularly children in developing countries. Currently, no approved Shigella vaccine exists.
Valneva will now lead the vaccine's development, including Phase 2 clinical trials, while LimmaTech will continue to be involved in the Phase 2 studies. The global market for a Shigella vaccine is estimated at over USD500m annually.
OnCusp Therapeutics' CUSP06 receives US FDA Fast Track Designation
Telix Pharmaceuticals' Illuccix receives UK regulatory approval
MimiVax reports positive interim analysis of SurVaxM Phase 2b clinical trial
Akeso enrols first patient in cadonilimab Phase 3 clinical trial
AbbVie and Xilio Therapeutics announce collaboration to develop tumour-activated immunotherapies
TriNetX and Fujitsu form joint venture to enhance clinical research in Japan
Oxford BioDynamics announces distribution agreement with Regina Maria for EpiSwitch tests in Romania
Lytix Biopharma secures US patent allowance for LTX-315 clinical programme
GenSight Biologics reports positive five-year resultsfor LUMEVOQ gene therapy
Health Canada approves Merck's KEYTRUDA for resectable non-small cell lung cancer
Owens & Minor launches ByramConnect digital health platform for diabetes management
Novartis to acquire Anthos Therapeutics in USD925m deal to expand cardiovascular pipeline
NLS Pharmaceutics and Kadimastem plan multi-target approach to diabetes
Hoth Therapeutics and OnTargetx R&D partner on cancer research
CStone Pharmaceuticals' Cejemly included in ESMO NSCLC Living Guideline